Product Information
CEFPROZIL 250 MG/5 ML SUSP is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.2277 per ML under NDC 57237003550. Its NADAC has been published 652 times since Apr 9, 2014.
FDA first approved this application on Jan 30, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/5mL
Manufacturer
Rising Pharma Holdings Inc.NDC
57237003550
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CEFPROZILApproval Type
Generic (ANDA)
FDA Application
ANDA065381FDA Approved
1/30/2007
TE Code
AB
On Market Since
1/30/2007
Price Statistics
The NADAC for CEFPROZIL 250 MG/5 ML SUSP has been published 652 times since Apr 9, 2014, and over the history we have for it it has declined 60.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2277 per ML |
|---|---|
| All-time high | $0.5948 (Sep 10, 2014) |
| All-time low | $0.1534 (Aug 17, 2022) |
| 52-week high | $0.2680 |
| 52-week low | $0.2148 |
| Median price | $0.3488 |
| Average price | $0.3949 |
| Largest weekly change | +75.2% (Oct 19, 2022) |
| Weeks tracked | 652 |
| Tracking since | Apr 9, 2014 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 34% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cefprozil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFPROZIL 250 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CEFPROZIL 250 MG/5 ML SUSP, manufactured by Rising Pharma Holdings Inc., is $0.2277 per ML (NDC 57237003550), effective Sep 30, 2026.
How has the price of CEFPROZIL 250 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for CEFPROZIL 250 MG/5 ML SUSP has declined 60.1%. It has been tracked across 652 weekly CMS publications since Apr 9, 2014.
What are the highest and lowest recorded NADAC prices for CEFPROZIL 250 MG/5 ML SUSP?
Since Apr 9, 2014, the NADAC for CEFPROZIL 250 MG/5 ML SUSP has ranged from a low of $0.1534 (Aug 17, 2022) to a high of $0.5948 (Sep 10, 2014), with a median of $0.3488 per ML.
Are there cheaper alternatives to CEFPROZIL 250 MG/5 ML SUSP?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CEFPROZIL 250 MG/5 ML SUSP, is $0.1511 per ML — about 34% below CEFPROZIL 250 MG/5 ML SUSP.
Who manufactures CEFPROZIL 250 MG/5 ML SUSP?
CEFPROZIL 250 MG/5 ML SUSP (NDC 57237003550) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.